Table 4. Gene classification based on canonical signaling pathways identified by Ingenuity pathway analysis (IPA).
| Ingenuity Canonical Pathways | P-values | Molecules ‡ |
|---|---|---|
| Activation of IRF by Cytosolic Pattern Recognition Receptors | 10.0×10–08 | MDA-5, RIG-I, DAI, STAT2, IRF9, TBK1, IRF3, ADAR1, ISG-54, ISG15 |
| Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses | 7.0×10–07 | MDA-5, OAS1, OAS2, RIG-I, DECTIN-2, C1QC, C1QB, IRF3, EIF2AK2, RNASEL, C3AR1 |
| Interferon Signaling | 2.1×10–05 | IFIT3, IFIT1, OAS1, MX1, STAT2, IRF9 |
| Role of RIG-I-like Receptors in Antiviral Innate Immunity | 8.7×10–04 | MDA-5, RIG-I, TBK1, IRF3, TRIM25 |
| Riboflavin Metabolism | 0.004 | FLAD1, ENPP1, ACP6 |
| Communication between Innate and Adaptive Immune Cells | 0.005 | CXCL10, TLR10, CD40LG, IL1A, HLA-A, FCER1G |
| Dendritic Cell Maturation | 0.006 | CD40LG, IL1A, HLA-A, CD1A, FCER1G, STAT2, CREB3L4 , FCGR3A |
| Graft-versus-Host Disease Signaling | 0.008 | IL1A, HLA-A, FCER1G, GZMB |
| Autoimmune Thyroid Disease Signaling | 0.008 | CD40LG, HLA-A, FCER1G, GZMB |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 0.010 | CD40LG, IL1A, CTGF, MYL4, FGFR2, IGFBP5, A2M |
| cAMP-mediated signaling | 0.011 | P2RY13, TULP2, PRKAR2B, CCR4, PDE3B, ADCY6, CREB3L4, CNGA3, MPPE1 |
| Sphingolipid Metabolism | 0.012 | CERS6, ARSJ, SGPP1, PPAP2C , SMPD3 |
| G-Protein Coupled Receptor Signaling | 0.014 | CALCRL, GPR15, ADCY6, CREB3L4, MPPE1, ADRA1D, P2RY13, TULP2, PRKAR2B, CCR4, PDE3B, GPR126, CCR8, HRH4, C3AR1, GPR143 |
| Altered T Cell and B Cell Signaling in Rheumatoid Arthritis | 0.016 | TLR10, CD40LG, IL1A, SPP1 (includes EG:20750),FCER1G |
| Complement System | 0.018 | C1QC, C1QB, C3AR1 |
| Nitrogen Metabolism | 0.023 | MARC1, ADAR, GLS2 |
| NF-κB Signaling | 0.024 | TLR10, CD40LG, IL1A, FCER1G, FGFR2, TBK1, EIF2AK2 |
| Cardiac β-adrenergic Signaling | 0.255 | TULP2, PRKAR2B, PDE3B, ADCY6, GNG7, MPPE1 |
| Relaxin Signaling | 0.026 | TULP2, PRKAR2B, PDE3B, ADCY6, GNG7, MPPE1 |
| Alanine and Aspartate Metabolism | 0.028 | DDO, AGXT2, ASL |
| Protein Kinase A Signaling | 0.040 | TULP2, PRKAR2B, ADD2, PDE3B, ADCY6, MYL4, CREB3L4, CNGA3, GNG7, MPPE1 |
| VDR/RXR Activation | 0.044 | CXCL10, SPP1 (includes EG:20750), CYP24A1, IGFBP5 |
| Lipid Antigen Presentation by CD1 | 0.049 | CD1A, FCER1G |
‡Genes more highly expressed in the Suffolk breed are in bold while genes that are more highly expressed in the Texel breed are in normal typeface.